KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Capital Employed (2021 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Return on Capital Employed for 5 consecutive years, with 0.61% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Capital Employed changed N/A year-over-year to 0.61%, compared with a TTM value of 0.61% through Sep 2025, changed N/A, and an annual FY2024 reading of 0.55%, changed N/A over the prior year.
  • Return on Capital Employed was 0.61% for Q3 2025 at Recursion Pharmaceuticals, down from 0.57% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.23% in Q3 2021 and bottomed at 0.61% in Q3 2025.
  • Average Return on Capital Employed over 5 years is 0.42%, with a median of 0.44% recorded in 2022.
  • Peak annual rise in Return on Capital Employed hit 2bps in 2022, while the deepest fall reached -22bps in 2022.
  • Year by year, Return on Capital Employed stood at 0.31% in 2021, then crashed by -42bps to 0.44% in 2022, then dropped by -17bps to 0.52% in 2023, then decreased by -3bps to 0.53% in 2024, then decreased by -14bps to 0.61% in 2025.
  • Business Quant data shows Return on Capital Employed for RXRX at 0.61% in Q3 2025, 0.57% in Q2 2025, and 0.46% in Q1 2025.